Psychemedics (PMD) & OpGen (NASDAQ:OPGN) Head to Head Analysis

Share on StockTwits

Psychemedics (NASDAQ:PMD) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends and institutional ownership.

Dividends

Psychemedics pays an annual dividend of $0.72 per share and has a dividend yield of 4.2%. OpGen does not pay a dividend.

Volatility & Risk

Psychemedics has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, OpGen has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.

Profitability

This table compares Psychemedics and OpGen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Psychemedics 14.24% 26.58% 18.41%
OpGen -395.63% -238.35% -118.17%

Earnings & Valuation

This table compares Psychemedics and OpGen’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Psychemedics $39.70 million 2.36 $6.12 million N/A N/A
OpGen $3.21 million 4.85 -$15.41 million ($9.78) -0.18

Psychemedics has higher revenue and earnings than OpGen.

Analyst Recommendations

This is a breakdown of recent recommendations for Psychemedics and OpGen, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Psychemedics 0 0 0 0 N/A
OpGen 0 0 1 0 3.00

OpGen has a consensus target price of $6.00, indicating a potential upside of 233.33%. Given OpGen’s higher probable upside, analysts clearly believe OpGen is more favorable than Psychemedics.

Institutional and Insider Ownership

56.3% of Psychemedics shares are held by institutional investors. Comparatively, 4.1% of OpGen shares are held by institutional investors. 9.9% of Psychemedics shares are held by company insiders. Comparatively, 7.1% of OpGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Psychemedics beats OpGen on 9 of the 13 factors compared between the two stocks.

About Psychemedics

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts.

About OpGen

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel in vitro diagnostic test designed to detect bacterial nucleic acids; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment. Further, it engages in the development of Acuitas Rapid Test designed to detect urinary tract infection. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

Receive News & Ratings for Psychemedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply